Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Balversais an oral anti-cancer star targeting FGFR mutations, which has a signif···【more】
Release date：2024-08-27Recommended：224
Balversa is an oral anticancer drug that specializes in FGFR mutant tumors, such···【more】
Release date：2024-08-27Recommended：228
Balversa is an oral anticancer drug used for the treatment of locally advanced o···【more】
Release date：2024-08-27Recommended：186
Accurately understanding the dosage of Balversa is the key to achieving the best···【more】
Release date：2024-08-27Recommended：163
Mastering the correct use of Balversais the first step to ensuring efficacy and ···【more】
Release date：2024-08-27Recommended：180
In-depth analysis of the treatment of Balversa, the primary concern is its recom···【more】
Release date：2024-08-27Recommended：244
Alpelisib effectively treats patients with HR/HER2- breast cancer harboring PIK3···【more】
Release date：2024-08-26Recommended：247
As the first PI3Kα inhibitor, Alpelisib has shown significant efficacy in the tr···【more】
Release date：2024-08-26Recommended：261
Alpelisib, approved in 2019, has a unique efficacy against PIK3CA mutant breast ···【more】
Release date：2024-08-26Recommended：203
Alpelisib is the first PI3K inhibitor specifically for PIK3CA-mutated breast can···【more】
Release date：2024-08-26Recommended：179
Alpelisib was approved by the FDA in 2019 for the treatment of breast cancer pat···【more】
Release date：2024-08-26Recommended：205
Alpelisib is the first PI3Kα inhibitor to be used in combination with fulvestran···【more】
Release date：2024-08-26Recommended：262
